Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,501–2,600 of 3,636
Cha, J., Hong, S. J., Lim, S., Kim, J. H., Joo, H. J., Park, J. H., Yu, C. W., Lim, D., Kim, J., Jeong, J., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0036 · Cited by 2
“13)20)21) Ezetimibe is an inhibitor of cholesterol absorption.”
BackgroundBershtein, L. L., Lunina, M. D., Евдокимов, Д. С., Найден, Т. В., Gumerova, V. E., Кочанов, И. Н., Ivanov, A. A., Афанасьевна, Б. С., Денисовна, Р. Е., Владимировна, З. Е., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-4005 · Cited by 2
Conroy, R., Mackie, S. A., & Boney, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_32 · Cited by 2
Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin
Katzmann, J. L., Ference, B. A., & Laufs, U. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0328-z · Cited by 3
Butty, A., Gencer, B., Koskinas, K. C., Carballo, D., Räber, L., Klingenberg, R., Matter, C. M., Lüscher, T. F., Windecker, S., Müller, O., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.012 · Cited by 3
Sabouret, P. F., Angoulvant, D., Pathak, A., Costa, F., Pezel, T., & Michos, E. D. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0627-8 · Cited by 3
Alirocumab after Acute Coronary Syndrome. Reply.
Schwartz, G. G., Steg, P. G., & Szarek, M. J. (2019) · PubMed · doi:10.1056/nejmc1902955
Rabaeus, M., & de Lorgeril, M. (2019) · Journal of Controversies in Biomedical Research · doi:10.36255/jcbmr.2019.35 · Cited by 3
“The ODYSSEY trial was a randomized, double-blind study involving 18,924 patients who had an ACS 1–12 months earlier.”
BackgroundMethodInfluentialChionchio, A., Galmer, A. M., & Hirsh, B. J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0791-7 · Cited by 4
Current and future trends in the treatment of dyslipidemias
Vrablík, M. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.112 · Cited by 4
Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia
Athyros, V. G., Boutari, C., Imprialos, K. P., & Doumas, M. N. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118999200428225849 · Cited by 2
Zhuravleva, M. V., Prokofiev, A. B., Ших, Е. В., Serebrova, S. Y., Gorodetskaya, G. I., & Demchenkova, E. Y. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-08-21 · Cited by 2
Residual inflammatory risk: Lessons from trials for the future
Stock, J. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.019 · Cited by 2
Masana, L., López‐Miranda, J., Civeira, F., Reinares, L., Guijarro, C., Plana, N., Cuenca, R., Sánchez, D. L., Hernández, J. L., de Andrés, R., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.02.004 · Cited by 2
Feldman, D. I., Michos, E. D., Stone, N. J., Gluckman, T. J., Cainzos‐Achirica, M., Virani, S. S., & Blumenthal, R. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100117 · Cited by 3
“In the ODYSSEY OUTCOMES trial, patients with an ACS within the preceding 1–12 months on statin therapy and an LDL-C 70 mg/dL were randomized to alirocumab or placebo [32].”
MethodЦукровий діабет і хронічний коронарний синдром
Serhiyenko, V. A., & Serhiyenko, A. A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.1.2021.226431 · Cited by 2
Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?
Deshotels, M. R., Virani, S. S., & Ballantyne, C. M. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01545-9 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
What’s new on therapies for elevated lipoprotein(a)
Ward, N. C., Schultz, C. J., & Watts, G. F. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1610391 · Cited by 2
Acute coronary syndromes: a success story but still a long way to go
Shaw, J. A., & Warren, J. (2019) · Heart · doi:10.1136/heartjnl-2019-316006 · Cited by 2
Karalis, D. G. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.08.008 · Cited by 2
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1874350 · Cited by 2
“The industry funded European Society of Cardiology and European Atherosclerosis Society may not provide an independent guideline [10,11].”
BackgroundAgha, A. M., & Ballantyne, C. M. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa021 · Cited by 2
Gao, F., Wang, Z. J., Ma, X., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-685343/v1 · Cited by 2
Bagepally, B. S., & Sasidharan, A. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/mw8y4 · Cited by 2
Dai, Y., & Ge, J. (2022) · Cardiology Plus · doi:10.1097/cp9.0000000000000005 · Cited by 2
Kraler, S. C., Sawamura, T., Harn, G. Y.-S., Chen, C., & Akhmedov, A. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1245716 · Cited by 2
Proprotein convertase subtilisisn/kexin type 9 inhibitors: the earlier the better?
Pirillo, A., & Catapano, A. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae206 · Cited by 2
Rivera, F. B., Cha, S. W., Magalong, J. V., Tang, V. A. S., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N. J., & Shah, N. P. (2024) · medRxiv · doi:10.1101/2024.07.10.24310245 · Cited by 2
Is PCSK9 the Key Player in the Ischemia-Reperfusion Match?
Benedetti, A., & Monte, A. D. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017210 · Cited by 2
Purvis, G. S. D., Jiang, J., Hiron, T. K., Karali, C. S., Baxter, M. D., Li, R., Vijjhalwar, R., Diotallevi, M., Draycott, S. A. V., Chuaiphichai, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.15.676283 · Cited by 2
Clinical Guidelines as a Continuous Work in Progress: Moving at the Speed of Science
Blumenthal, R. S., & Morris, P. B. (2026) · Circulation · doi:10.1161/cir.0000000000001429 · Cited by 2
IgG Propels Atherosclerosis by Noncanonically Activating MacrophagesPreprint
Zahr, T., Zhang, K., Huang, S., Xue, C., Yu, L., Yu, Z., Li, B., Liang, D., Wang, Q., Shadrina, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.13.711718 · Cited by 2
Finny, A. S. (2026) · doi:10.59350/ppf5a-hvf03 · Cited by 2
Souček, M., & Novák, J. (2020) · Medicína pro praxi · doi:10.36290/med.2020.018 · Cited by 1
Management of Statin Intolerance
Bartłomiejczyk, M. A., Penson, P. E., & Banach, M. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_12 · Cited by 1
Javed, M., Bhatti, I. A., Jaffar, N., Haider, G., Irshad, Z., & Haroon, S. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93986 · Cited by 2
Nicot, F., Charbonnel, C., Jégo, C., et al. (2021) · Echocardiography · doi:10.1111/echo.15034 · Cited by 1
Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke
Zhang, D., Song, X., Raposeiras‐Roubín, S., et al. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211046999 · Cited by 1
Yamada, R., Kume, T., Okamoto, H., Yamashita, M., Koto, S., Kamisaka, K., Sasahira, Y., Sudo, Y., Enzan, A., Tamada, T., et al. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.21 · Cited by 2
Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient
Gargiulo, G., & Esposito, G. (2022) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2022.2391 · Cited by 1
Lipid-Lowering Therapy Seen Through the Lens of Experts: Expectations Thwarted by Reality
Kaiser, S. E. (2022) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2022.22662 · Cited by 1
The Role of Monoclonal Antibodies in the Treatment of Atherosclerosis
Hong, J. M., Salazar, L., Acevedo, J., Thakker, R. A., Jneid, H. M., Shalaby, M., McCracken, J. L., & Khalife, W. I. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101585 · Cited by 1
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.1.2023.1242 · Cited by 1
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_40 · Cited by 1
Clinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 3
Gilyarevsky, S. R., & VIu, M. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5422 · Cited by 1
PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
Nekipelova, A. A., & Alyautdin, R. N. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-279-291 · Cited by 1
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1
Dyslipidaemia in elderly and stroke patients
Kahali, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.013 · Cited by 2
Management of dyslipidemia in special groups
Jayagopal, P. B., & Kerkar, P. G. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.018 · Cited by 1
Avlasevich, V., Pilat, S., Reindel, K., et al. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae033 · Cited by 1
Rallis, D., Papathanasiou, A. E., & Christou, H. A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae031 · Cited by 1
“In human studies in adults, serum PCSK9 levels are positively associated with acute myocardial infarction [27] and high-sensitivity C-reactive protein levels [28], whereas PCSK9 inhibitors such as evolocumab or alirocumab reduce the risk of recurrent ischemic cardiovascular events [29, 30].”
BackgroundZhang, G., Chang, S., Zhao, F., Guan, X., Nie, Z., Liu, W., & Li, B. (2024) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000108 · Cited by 1
“[32] 2018 57 Countries ACS 9462/9462 58.5 ± 9.3/ 58.6 ± 9.4 Alirocumab/matchingplacebo 33.60 I, II, III, IV, V, VI NCT01663402 RCT Yan et al. [33] 2022 China Extremely high-risk ACS 68/68 62.2 ± 12.3/ 62.2 ± 11.4 Evolocumab/matchingplacebo 3.00 I, II, III, IV, V, Unclear RCT Zhang et al. [34]…”
InfluentialZhao, J., Tong, X., Peng, J., Lyu, C., & Lu, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2503094 · Cited by 1
“[ 16].”
BackgroundInfluentialKLE Academy of Higher Education and Research’s Scholarly Research Trends: Bibliometric Study
Kumara, B. M. P., & Patil, M. M. (2024) · Journal of the Scientific Society · doi:10.4103/jss.jss_24_23 · Cited by 1
Bempedoic acid: A new player in lipid-lowering
Riesen Walter, F. (2024) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000205 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
van Bruggen, F. H., Zuidema, S. U., & Luijendijk, H. J. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02260-z · Cited by 3
“After full-text assessments, we included 43 completed trials with 63,193 participants [4, 5, 7, 8, 28– 66 ].”
BackgroundMethodInfluential7000 Miles on One Tank of Gas: Inclisiran—Amazing for Cholesterol but Outcome Data Needed
Brady, A. J. B. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.06.010 · Cited by 1
Kommentar zu den Leitlinien (2023) der ESC zum Akuten Koronarsyndrom (ACS)
Waßmann, S., Giménez, M. R., Cassese, S., Ghanem, A., Schüpke, S., Ong, P., Schirmer, S. H., Thiele, H., & Mehilli, J. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00705-9 · Cited by 2
Baviera, M., Foresta, A., Fernandez, M. L. O., Torrigiani, G., Tettamanti, M., Roncaglioni, M. C., Cimminiello, C., PAD, C. A. D. S. G., Aronica, A., Cascini, V., et al. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03771-9 · Cited by 2
Management of cardiometabolic diseases: A clinician's perspective
Bassi, N. S., Mohan, P., & Itchhaporia, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00002-4 · Cited by 1
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
Geba, G. P., Chen, R., Talapatra, K., Brackin, T., Mohammadi, K. A., Pordy, R. C., Manvelian, G. Z., Maron, D. J., Schwartz, G. G., Szarek, M. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100900 · Cited by 1
Self-citationLipid‐Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity
Gordon‐Kundu, B., Peyravi, R., Garg, A., Baker, A. D., Salas, S., Levien, M., Faridi, K. F., de Havenon, A., Krumholz, H. M., Sheth, K. N., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033365 · Cited by 2
“23,24 Despite the substantial body of evidence demonstrating the efficacy of LLT use in at-risk patients to prevent ASCVD including stroke, LLT was underused prestroke among those eligible in our study.”
Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities
Akkuş, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336501241001093417 · Cited by 4
Mert, G. Ö., Mert, K. U., Başaran, Ö., Doğan, V., Rencüzoğulları, İ., Özlek, B., Çinier, G., Özlek, E., Biteker, M., Kayıkçıoğlu, M., et al. (2025) · Coronary Artery Disease · doi:10.1097/mca.0000000000001493 · Cited by 2
Wang, X., Liu, C., Yu, F., Zhang, Z., Wang, J., Shi, X., Xu, T., Deng, Q., Zhou, L., Sang, W., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25984 · Cited by 1
Eficacia y seguridad de los inhibidores de la PCSK9 en la vida real
González-Guerrero, A., Navarrete-Rouco, E., Benaiges, D., Steinhauer, E. G., Marcos, L., Oliveras, A., Recasens, L., & Pedro‐Botet, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.500755 · Cited by 5
Cardozo, F. A. M., Bichuette, L. D., & Caramelli, B. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2463348 · Cited by 1
“Similar to evolocumab, injection site reactions were the primary adverse effect (3.8% vs. 2.1%; p < 0.001) [27].”
InfluentialRay, R., Mahmood, A., Chaudhry, R., Masmoum, M. D., Talha, M., Siddiqui, F. I., & Ullah, I. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x345749250122092324 · Cited by 1
Cinza‐Sanjurjo, S., Pallarés‐Carratalá, V., Rodríguez, Á. D., Fierro-González, D., Turégano-Yedro, M., & García, J. P. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102460 · Cited by 2
Iakoubova, O. A., Sheikhi, F. H., Louie, J. Z., Rowland, C. M., Arellano, A. R., Bare, L. A., Birse, C. E., & Penn, M. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-89373-7 · Cited by 1
“Indeed, the residual risk remaining after treatment is often greater than risk that is eliminated 50–53 .”
Apolipoprotein C3 and cardiovascular risk: new insights from the ODYSSEY outcomes trial
Catapano, A. L., Pirillo, A., & Tokgözoğlu, L. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf202 · Cited by 1
Malick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 3
Amariței, O., Mierlan, O. L., Guțu, C., & Gurău, G. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050169 · Cited by 2
“It also highlights the insufficient research into the relationship between PCSK9-i and Lp(a) [5].”
InfluentialArai, R., Hotsubo, Y., Nakajima, Y., Sumida, R., Mizobuchi, S., Migita, S., Tanaka, Y., Hori, K., Fukumoto, K., Ebuchi, Y., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65731 · Cited by 1
“However, these pivotal trials excluded patients within the first month of AMI, leaving uncertainty regarding the efficacy of initiating PCSK9 inhibitors during hospitalization 5, 6) .”
Patra, V., Yella, V. R., Konda, V. G. R., Sayana, S. B., Siripuram, C., Konka, S., & Kandimalla, R. J. L. (2025) · Cureus · doi:10.7759/cureus.86310 · Cited by 1
“These findings emphasize the role of alirocumab in secondary prevention, particularly in high-risk individuals inadequately controlled with statins alone [10].”
InfluentialCancelli, G., Rossi, C. S., FILIPPO, O. D., Franco, A. D., Harik, L., Borzillo, I., Hirofuji, A., Soletti, G. J., Mantaj, P., Cangut, B., et al. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.05.009 · Cited by 2
Pindwarawala, M., Bose, S., & Brunham, L. R. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.103953 · Cited by 2
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00077-9 · Cited by 1
Sanyaolu, S. E., Wilson, D. O., Oguntolu, B. A., Salako, M. S., & Adeyemi, R. (2025) · Premier Journal of Cardiology · doi:10.70389/pjc.100011 · Cited by 2
Knöchel, J., Nilsson, C. A. M., Carlsson, B., Hofherr, A., Johanson, P., Rydén‐Bergsten, T., Hamrén, B., & Rekić, D. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70076 · Cited by 1
Wang, C., Cui, L., Ma, X., Sun, M., Wang, Y., Dong, F., Zhao, C., Tian, X., Wang, Y., Zhang, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04346-x · Cited by 1
Geba, G. P., Mohammadi, K. A., Damask, A., Paulding, C., Lotta, L. A., Hindy, G., Pordy, R. C., Manvelian, G. Z., Shapiro, M. D., Bittner, V., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.041190 · Cited by 4
Self-citationMostaza, J. M., Lahoz, C., Castro, M. G. D. Y., Campal, J. M. R., Velásquez, E., Gutiérrez, A. I., Díaz, J. F., Plana, N., Rodríguez‐Mañero, M., García-Díaz, J. D. D. D., et al. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502344 · Cited by 1
Niu, Q., Wang, Q., Chen, F., & Li, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1626681 · Cited by 1
“Previous studies have consistently demonstrated the potent LDL-C lowering effects of statins and PCSK9 inhibitors (Sabatine et al., 2017; Schwartz et al., 2018; Raal et al., 2020; Cannon et al., 2004; LaRosa et al., 2005; Nissen et al., 2006).”
Colet, J. C., Freixa‐Pamias, R., García-Muñoz, N., Mallén-Alberdi, M., Montaño, J., Gaugris, S., Mistry, C., Tilley, L., Vitale, G. C., & López, S. G. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2557717 · Cited by 3
“However, it is important to highlight that while REDUCE-IT and ODYSSEY OUTCOMES defined recent ACS as MI or unstable angina occurring within the previous 12 months, the ezetimibe trial defined recent ACS more narrowly, as a hospitalization for ACS within the preceding 10 days 7,8 .”
Biscetti, F., Rando, M. M., Nicolazzi, M. A., Polito, G., Pecorini, G., Angelini, F., Iezzi, R., Eraso, L. H., DiMuzio, P. J., Pitocco, D., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2717-3194 · Cited by 1
Myerson, M. L., Warden, B. A., Saseen, J. J., & Paparodis, R. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044134 · Cited by 2
“30,31 Inclisiran is the newest LDL-C lowering medication.”
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Hu, F., Wu, R., Zhao, X., Zhao, Y.-K., Zhou, J., Hu, B., Li, A., & Sun, Y. (2025) · Translational Stroke Research · doi:10.1007/s12975-025-01367-9 · Cited by 3
“Additionally, in the trial by Schwart et al., many people continued to experience cardiovascular events or disease progression, despite using maximum tolerated doses of newer statins to reduce LDL-C [18].”
Woźniak, E., Woźniak, A., Pawlos, A., Broncel, M., Satała, J., Bukowska, B., & Gorzelak‐Pabiś, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110529 · Cited by 2
Montalescot, G., Bolognese, L., Bartuś, S., Cequier, A. R., Thiele, H., Mach, F., Jukema, J. W., Ferrari, É., Souteyrand, G., Bouleti, C., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107295 · Cited by 2
Self-citationLipid-lowering therapy in Switzerland: time trends in utilization and cost, 2015–2023
Wolf, S., Zufferey, J., Kucher, N., Lüscher, T. F., & Barco, S. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02786-1 · Cited by 1
“…convertase subtilisin/kexin type 9 (PCSK9) inhibitors were introduced, potent antibodies for further LDL-C reduction, for which two seminal large controlled randomized trials (FOURIER and ODYSSEY) [8, 9] demonstrated additional cardiovascular event reductions when added to statin therapy [10].”
Uddin, M., Shah, A., Hemida, M. F., Afridi, M. J., Bacha, Z., Iftikhar, H., Khan, S., Saif, H., Jamal, A., Syed, A., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.012 · Cited by 1
Jing, A., Wang, J., Zhang, M., Liang, Y., Liu, J., Zhang, N., Wang, J., Li, X., Li, C., Cui, Z., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-26495-y · Cited by 1
“…that PCSK9 inhibitors (PCSK9i) can effectively reduce the risk of recurrent ischemic cardiovascular events in patients with a history of acute coronary syndrome (ACS) who are receiving high-intensity statins therapy, showing significant clinical advantages compared to those receiving a placebo 16 .”
Adili, N., Zhao, Q., Aihemaiti, G., Chu, J.-K., Zhang, J.-K., Yang, Y., & Li, X. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01160-2 · Cited by 1
“Many clinical studies support the role of inflammation in CAD [9, 39–41].”
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Liu, L., Yan, Q., Li, M., & Ai, J. (2025) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2025.101964 · Cited by 1
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

